Bal Pharma Ltd.
| BSE: 524824 | Sector: Health care |
| NSE: BALPHARMA | ISIN Code: INE083D01012 |
| BSE 00:00 | 20 May | 102.90 |
1.20 (1.18%) |
OPEN
101.85 |
HIGH
105.00 |
LOW
101.80 |
| NSE 00:00 | 20 May | 104.05 |
2.80 (2.77%) |
OPEN
102.00 |
HIGH
105.00 |
LOW
102.00 |
| OPEN | 101.85 |
| PREVIOUS CLOSE | 101.70 |
| VOLUME | 3612 |
| 52-Week high | 148.50 |
| 52-Week low | 88.00 |
| P/E | 15.73 |
| Mkt Cap.(Rs cr) | 160 |
| Buy Price | 0.00 |
| Buy Qty | 0.00 |
| Sell Price | 0.00 |
| Sell Qty | 0.00 |
Bal Pharma Ltd. (BALPHARMA) - Latest News & Headlines
-
Bal Pharma Ltd Certificate As Per Regulation 40(9) Of SEBI(LODR) Regulations2015.
19/04/2022 | bse |
Downlaod PDF -
Bal Pharma Ltd Announcement under Regulation 30 (LODR)-Allotment
13/04/2022 | bse |
Downlaod PDF -
Bal Pharma Ltd Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
13/04/2022 | bse |
Downlaod PDF -
Bal Pharma Ltd Compliance With Regulation 7(3) Of SEBI(LODR) Regulations.
06/04/2022 | bse |
Downlaod PDF -
Bal Pharma Ltd Board Meeting Intimation for Allotment Of Equity Shares Upon Conversion Of Warrants.
05/04/2022 | bse |
Downlaod PDF
-
Ruchi Soya acquires Patanjali Ayurved's food business for Rs 690 crore
1.32 am | 19 May 2022 | Business Standard
To pay 1% of turnover of products as annual royalty under transfer agreement
-
Ruchi Soya hits upper circuit on buyout of Patanjali's food retail business
3.58 pm | 18 May 2022 | Business Standard
The board also approved to change company's name from Ruchi Soya Industries to Patanjali Foods.
-
Gokaldas Exports surges 9%; hits all-time high on healthy business outlook
10.17 am | 18 May 2022 | Business Standard
A shift in consumer preferences post pandemic towards wovens, as people seek more formal clothes, may improve demand.
-
UltraTech, JSW lost Ambuja race due to CCI concerns: Holcim CEO
1.44 am | 18 May 2022 | Business Standard
The CEO said the smoothness of the execution of such a transaction was a major factor in taking the decision.
-
Street betting on revival of metals cycle amid buzz of over-correction
11.42 pm | 17 May 2022 | Business Standard
High input costs leading to margin pressure, lower-than-expected realisations are among downside risks
Quick Links for Bal Pharma:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
